
JW Pharmaceutical’s anti-gout drug URC102 been given certification from the European Patent Place of work (EPO) as a supply technology.





The patent is the company’s system to put together a compound that works as the key component and intermediate of URC102. URC102, formulated as a new oral drug, inhibits uric acid transporter-1 (URAT1) and is powerful for gout people induced by abnormally elevated uric acid concentrations in the blood, JW Pharm reported.


The firm licensed out the legal rights to create and commercialize URC102 in China, like Hong Kong and Macau, to China’s Nanjing Simcere Dongyuan Pharmaceutical in 2019. In addition, it is pursuing international engineering transfer based mostly on the benefits of phase 2 medical trials done in Korea.


With the the latest EPO’s final decision, JW Pharmaceutical options to acquire methods for required procedures to thoroughly acquire the patent in important European countries in the long run.


“We are earning progress in obtaining the patent for the technological innovation of URC102 without having any setback, and we will continue to develop URC102 as a world-wide gout drug with superior protection and outstanding efficacy,” a JW Pharmaceutical formal explained.


The firm registered the technological know-how in Australia in 2020 and the Republic of South Africa in April. It also applied for patents in 20 nations, which includes Korea, the U.S., Japan, and China.
More Stories
Vacasa to Current at Citi’s 2021 World wide Technologies Meeting
International Technologies Pioneers Licella Announce Commissioning of World’s Biggest Running Hydrothermal Liquefaction Facility
Vacasa to Existing at Citi’s 2021 World-wide Technologies Conference